Yuxuebi tablet + Placebo tablet
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ankylosing Spondylitis
Conditions
Ankylosing Spondylitis
Trial Timeline
Jul 1, 2021 → Jan 31, 2022
NCT ID
NCT04934059About Yuxuebi tablet + Placebo tablet
Yuxuebi tablet + Placebo tablet is a approved stage product being developed by China Resources Pharmaceutical Group for Ankylosing Spondylitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04934059. Target conditions include Ankylosing Spondylitis.
What happened to similar drugs?
12 of 20 similar drugs in Ankylosing Spondylitis were approved
Approved (12) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
20
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04934059 | Approved | UNKNOWN |
Competing Products
20 competing products in Ankylosing Spondylitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab | Celltrion | Phase 1 | 29 |
| Infliximab | Celltrion | Phase 1 | 29 |
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 27 |
| adalimumab | Eisai | Phase 3 | 40 |
| Ixekizumab + Placebo + Adalimumab | Eli Lilly | Phase 3 | 32 |
| Tramadol /acetaminophen + Diclofenac | Johnson & Johnson | Approved | 35 |
| Golimumab + Placebo | Johnson & Johnson | Phase 3 | 40 |
| Golimumab | Johnson & Johnson | Approved | 43 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 38 |
| placebo for risankizumab + risankizumab | AbbVie | Phase 2 | 35 |
| Adalimumab | AbbVie | Approved | 39 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| infliximab + Placebo | Merck | Phase 3 | 40 |
| Infliximab | Merck | Approved | 35 |
| Infliximab + Placebo + Naproxen | Merck | Phase 3 | 40 |
| Infliximab | Merck | Pre-clinical | 26 |
| Golimumab | Merck | Approved | 43 |
| Remicade | Merck | Approved | 43 |
| Remicade | Merck | Approved | 43 |